Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer

Kim, Junghwan; Oh, Sung Yong; Kwon, Hyuk‐Chan; Lee, Suee; Kim, Sung-Hyun; Kim, Dae‐Cheol; Lee, Jinhwa; Lee, Hyung-Sik; Cho, Se-Heun; Kim, Hyojin

doi:10.4143/crt.2008.40.3.101

Cited by 9 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The commonly used agents include capecitabine, vinorelbine, gemcitabine, pegylated liposomal doxorubicin, irinotecan, and ixabepilone [17]. The current study confirms the previous reports that combination chemotherapy with gemcitabine and cisplatin [13,[18][19][20][21][22]. These discordant results may be due to the small patient numbers, the heterogeneous patient populations and differing selection criteria.…”

Section: Discussionsupporting

confidence: 85%

Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer

et al. 2011

View full text Add to dashboard Cite

This study was conducted to evaluate the response rate of gemcitabine and cisplatin as second-line combination chemotherapy in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Thirty-eight eligible women with measurable disease and anthracycline- and taxane-pretreated MBC were enrolled. The chemotherapy treatment consisted of gemcitabine (1,250 mg/m(2) by intravenous infusion over 30 min on days 1 and 8) and cisplatin (75 mg/m(2) by intravenous infusion over 1 h on day 1), which were administered every 21 days. Thirty-seven of 38 (97.4%) of patients were assessable for response. The objective response rate was 42.1% (95% CI, 26.4-57.8%) with 16 partial responses. The median time to progression (TTP) and overall survival (OS) for all patients were 5.4 months (95% CI, 2.7-8.1 months) and 13.9 months (95% CI, 9.4-18.4 months), respectively. The most frequent hematologic-related adverse events were grade 3/4 leucopenia and thrombocytopenia, observed in 10 patients (27.0%) and 11 (29.7%), respectively. Grade 3 stomatitis was observed in 3 (8.1%) patients. No grade 4 nonhematologic toxicity was observed in this study. No treatment-related deaths occurred during the study. In conclusion, the combination of gemcitabine and cisplatin is a safe and tolerable regimen as second-line combination for patients with anthracycline- and taxane-pretreated MBC.

show abstract

Section: Discussionsupporting

confidence: 85%

Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In this study, P.S was the only significant prognostic factor for TTP; Kim et al 24 reported the same result.…”

Section: Resultssupporting

confidence: 71%

“…The difference in RR and OS observed among these studies, including this study, most likely reflect patient selection with good prognostic factors as longer disease free interval (DFI), higher percentage of patients who had one metastatic site, hormonal receptor positive and HER-2 negative. The lower RR in the study of Burch 23 and Kim et al 24 are due to the use of GP combination as a second line treatment for metastatic disease.…”

Section: Resultsmentioning

confidence: 82%

Prognostic Factors for Treatment Outcomes of First Line Chemotherapy in Metastatic Breast Cancer

Gamal¹,

Mostafa²

2011

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

“…The median TTP varied between 3.2 and 7.7 months, and median OS ranged from 7.4 to 19.5 months. The major toxicities were myelosuppression, peripheral neuropathy and nausea/vomiting (table 4) [83,84,85,86,87,88,89,90,91,92]. In the study by Nagourney et al [83], 13% of patients had grade III/IV neutropenia, 6% had anemia, 31% had thrombocytopenia, 4% had nausea/vomiting and 2% had peripheral neuropathy.…”

Section: Experience With Combination Chemotherapymentioning

confidence: 99%

“…In the study by Nagourney et al [83], 13% of patients had grade III/IV neutropenia, 6% had anemia, 31% had thrombocytopenia, 4% had nausea/vomiting and 2% had peripheral neuropathy. Most studies observed that this regimen is well tolerated, with grade III/IV leukopenia and thrombocytopenia being the most serious adverse events and nonhematological toxicity rarely being severe [86,87,88,89,90,91,92]. …”

Section: Experience With Combination Chemotherapymentioning

confidence: 99%

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Shamseddine¹,

Farhat²

2011

Chemotherapy

View full text Add to dashboard Cite

The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer (MBC) has been extensively studied. As single agents, high response rates have been observed in first-line therapy, while results in pretreated patients were discouraging. Regimens containing cisplatin/carboplatin together with taxanes showed the highest efficacy and safety as both first-line and second-line therapy. When administered with vinorelbine, the combination was also active and well tolerated in anthracycline- and taxane-pretreated patients. Combining PBCs with etoposide or nucleoside analogues showed moderate activity, yet high toxicity in the case of etoposide. The overall results for the combination with anthracyclines were disappointing. Addition of trastuzumab to PBC combinations showed remarkable activity and good tolerability in patients with HER2/neu overexpression. The use of cisplatin or carboplatin alongside novel targeted therapeutics for patients with triple-negative MBC seems promising and is being further evaluated. The use of PBCs against MBC requires careful patient selection and combination with the right chemotherapeutic agent.

show abstract

Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer

Cited by 9 publications

References 25 publications

Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer

Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer

Prognostic Factors for Treatment Outcomes of First Line Chemotherapy in Metastatic Breast Cancer

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Contact Info

Product

Resources

About